INS and metabolic syndrome: Oral hypoglycaemic drugs (but not insulin) were also found to have beneficial effects in this review, so the combination of multiple treatments for multiple risk factors in people with T2D may explain why the risks in this group are comparatively lower than prediabetes or MetS.